The Global Macroeconomic Burden of Breast Cancer: Implications for Oncologic Surgery. 2021

Kavitha Ranganathan, and Puneet Singh, and Krishnan Raghavendran, and Edwin G Wilkins, and Jennifer B Hamill, and Oluseyi Aliu, and Lisa A Newman, and David Hutton, and Adeyiza O Momoh
Department of Surgery, Michigan Medicine, Ann Arbor, MI.

In this study, we quantified the global macroeconomic burden of breast cancer to underscore the critical importance of improving access to oncologic surgical care internationally. Breast cancer mortality in many low and middle-income countries (LMICs) is dramatically higher than in high-income countries. Prior to identifying solutions, however, it is important to first define the burden of disease. Data from the Institute of Health Metrics and Evaluation (2005-2015) were used to assess epidemiologic trends for 194, middle, and low-income countries. Economic burden defined by Welfare Loss (WL) was calculated by measuring disability-adjusted-life-years lost to breast cancer alongside the dollar equivalent of a value of statistical life year and as a function of each country's gross domestic product (GDP). Annual mortality rates among breast cancer patients were significantly greater in LMICs in South Asia (3.06 per 100 women) and Sub-Saharan Africa (2.76 per 100 women), compared with high-income countries like the United States (1.69 per 100 women). From 2005-2015, mortality in South Asia increased by 8.20% and decreased by 6.45% in Sub-Saharan Africa; mortality rates in 2015 were observed as 27.9 per 100,000 in South Asia and 18.61 per 100,000 in Sub-Saharan Africa. Countries in South Asia demonstrated the greatest rise in WL due to breast cancer, from 0.05% to 0.08% of GDP. The burden of disease and economic impact of breast cancer is intensifying in LMICs. Global efforts to improve access to surgical care for women with breast cancer could reduce mortality and mitigate the social and financial impact of this disease in LMICs.

UI MeSH Term Description Entries
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071077 Surgical Oncology A surgical specialty concerned with management of cancer. Oncology, Surgical
D014943 Global Health A multi- and interdisciplinary field concerned with improving health and achieving equity in health for all people. It transcends national boundaries, promotes cooperation and collaboration within and beyond health science fields, and combines population-based disease prevention with individually-based patient care. International Health Problems,World Health,International Health,Worldwide Health,Health Problem, International,Health Problems, International,Health, Global,Health, International,Health, World,Health, Worldwide,Healths, International,International Health Problem,International Healths,Problem, International Health,Problems, International Health
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D019057 Quality-Adjusted Life Years A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services. (BIOETHICS Thesaurus, 1994) Adjusted Life Year,Healthy Years Equivalent,QALYs,QUALYs,Quality Adjusted Life Year,Quality-Adjusted Life Year,Adjusted Life Years,Healthy Years Equivalents,Quality Adjusted Life Years,Equivalents, Healthy Years,Life Year, Adjusted,Life Year, Quality-Adjusted,Life Years, Adjusted,Life Years, Quality-Adjusted,QUALY,Years, Adjusted Life

Related Publications

Kavitha Ranganathan, and Puneet Singh, and Krishnan Raghavendran, and Edwin G Wilkins, and Jennifer B Hamill, and Oluseyi Aliu, and Lisa A Newman, and David Hutton, and Adeyiza O Momoh
March 2024, Plastic and reconstructive surgery,
Kavitha Ranganathan, and Puneet Singh, and Krishnan Raghavendran, and Edwin G Wilkins, and Jennifer B Hamill, and Oluseyi Aliu, and Lisa A Newman, and David Hutton, and Adeyiza O Momoh
November 2025, International journal of surgery (London, England),
Kavitha Ranganathan, and Puneet Singh, and Krishnan Raghavendran, and Edwin G Wilkins, and Jennifer B Hamill, and Oluseyi Aliu, and Lisa A Newman, and David Hutton, and Adeyiza O Momoh
October 2022, Journal of neurosurgery,
Kavitha Ranganathan, and Puneet Singh, and Krishnan Raghavendran, and Edwin G Wilkins, and Jennifer B Hamill, and Oluseyi Aliu, and Lisa A Newman, and David Hutton, and Adeyiza O Momoh
June 2012, Future oncology (London, England),
Kavitha Ranganathan, and Puneet Singh, and Krishnan Raghavendran, and Edwin G Wilkins, and Jennifer B Hamill, and Oluseyi Aliu, and Lisa A Newman, and David Hutton, and Adeyiza O Momoh
July 2015, JAMA oncology,
Kavitha Ranganathan, and Puneet Singh, and Krishnan Raghavendran, and Edwin G Wilkins, and Jennifer B Hamill, and Oluseyi Aliu, and Lisa A Newman, and David Hutton, and Adeyiza O Momoh
September 2019, The Lancet. Planetary health,
Kavitha Ranganathan, and Puneet Singh, and Krishnan Raghavendran, and Edwin G Wilkins, and Jennifer B Hamill, and Oluseyi Aliu, and Lisa A Newman, and David Hutton, and Adeyiza O Momoh
May 1965, Prensa medica argentina,
Kavitha Ranganathan, and Puneet Singh, and Krishnan Raghavendran, and Edwin G Wilkins, and Jennifer B Hamill, and Oluseyi Aliu, and Lisa A Newman, and David Hutton, and Adeyiza O Momoh
February 2020, European journal of neurology,
Kavitha Ranganathan, and Puneet Singh, and Krishnan Raghavendran, and Edwin G Wilkins, and Jennifer B Hamill, and Oluseyi Aliu, and Lisa A Newman, and David Hutton, and Adeyiza O Momoh
January 2008, Voprosy onkologii,
Kavitha Ranganathan, and Puneet Singh, and Krishnan Raghavendran, and Edwin G Wilkins, and Jennifer B Hamill, and Oluseyi Aliu, and Lisa A Newman, and David Hutton, and Adeyiza O Momoh
March 2015, Annals of surgical oncology,
Copied contents to your clipboard!